Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease

Journal of the Neurological Sciences

Volumn 306, Issue 1-2, 2011, Pages 1-8

  Burbulla, Lena F ^a,b   Krüger, Rejko ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Environment; Genetics; Mitochondria; Parkinson's disease; Protein aggregation

Indexed keywords

CELL DEATH; CONFERENCE PAPER; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HEREDITY; HUMAN; MITOCHONDRION; MOTOR DYSFUNCTION; NERVE CELL; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIAL DISEASES; MUTATION; PARKINSON DISEASE; RISK FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 79958740737     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.04.005     Document Type: Conference Paper

References (115)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6. (Pubitemid 46184217)
2. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65:1436-41. (Pubitemid 41552776)
3. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994;44:266-8. (Pubitemid 24070964)
4. Katayama Y, Kasai M, Oshima H, Fukaya C, Yamamoto T, Ogawa K, et al. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients. J Neurosurg 2001;95:213-21. (Pubitemid 32799742)
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. (Pubitemid 36007810)
6. Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol 1996;69:3-11.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
8. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
9. Jenner P, Marsden CD. The actions of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in animals as a model of Parkinson's disease. J Neural Transm Suppl 1986;20:11-39.
10. Matzler W, Nagele T, Gasser T, Kruger R. Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology 2007;68:414. (Pubitemid 46208742)
11. Lopez-Alberola R, Georgiou M, Sfakianakis GN, Singer C, Papapetropoulos S. Contemporary Encephalitis Lethargica: phenotype, laboratory findings and treatment outcomes. J Neurol 2009;256:396-404.
12. Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007;64:666-72. (Pubitemid 47488093)
13. Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud JP, Delemotte B, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009;66:494-504.
14. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50:1346-50. (Pubitemid 28240350)
15. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007;64:990-7. (Pubitemid 47047999)
16. Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Rodriguez C, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004;160:977-84. (Pubitemid 39488426)
17. Troiano AR, Elbaz A, Lohmann E, Belarbi S, Vidailhet M, Bonnet AM, et al. Low disease risk in relatives of north african lrrk2 Parkinson disease patients. Neurology 2010;75:1118-9.
18. Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007;68:1141-3. (Pubitemid 46559849)
19. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365:412-5. (Pubitemid 40179228)
20. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med 2008;6:32.
21. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661-70. (Pubitemid 44200637)
22. Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 2005;57:535-41. (Pubitemid 40471163)
23. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003;60:796-801. (Pubitemid 36297363)
24. Abou-Sleiman PM, Muqit MM, McDonald NQ, Yang YX, Gandhi S, Healy DG, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006;60:414-9.
25. Kruger R. LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary. BMC Med 2008;6:33.
26. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, et al. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol 2011;69:778-92.
27. Maraganore DM, Hernandez DG, Singleton AB, Farrer MJ, McDonnell SK, Hutton ML, et al. Case-control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol 2001;50:658-61. (Pubitemid 33021924)
28. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genomewide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-12.
29. Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, et al. Genomewide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet 2011;20:615-27.
30. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011;377:641-9.
31. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7. (Pubitemid 27443610)
32. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-6. (Pubitemid 23354413)
33. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-72.
34. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
35. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73. (Pubitemid 38166992)
36. Polymeropoulos MH. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998;44:S63-4.
37. Kruger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, Woitalla D, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001;56:1355-62. (Pubitemid 32455298)
38. Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res 2000;61:121-7.
39. Seidel KSL, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, Dickson D, Gai W, Bornemann A, Riess O, Rami A, den Dunnen W, Deller T, Rüb U, Krüger R. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol 2010;67:684-9.
40. Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord 2005;20:1191-4.
41. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841. (Pubitemid 37339619)
42. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-9. (Pubitemid 39296604)
43. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 2006;59:298-309. (Pubitemid 43202483)
44. Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 2009;18:3274-85.
45. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 2001;10:3101-9. (Pubitemid 34083496)
46. Sotiriou S, Gibney G, Baxevanis AD, Nussbaum RL. A single nucleotide polymorphism in the 3?UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 2009;461:196-201.
47. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008;40:217-24. (Pubitemid 351171400)
48. Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, et al. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 2008;118:320-7.
49. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008;22:1327-34. (Pubitemid 351656774)
50. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010;67:1350-6.
51. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21. (Pubitemid 24309509)
52. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000;7:240-50.
53. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 1999;274:28849-52.
54. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8. (Pubitemid 28207717)
55. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5. (Pubitemid 30437317)
56. Um JW, Im E, Lee HJ, Min B, Yoo L, Yoo J, et al. Parkin directly modulates 26S proteasome activity. J Neurosci 2010;30:11805-14.
57. Olzmann JA, Chin LS. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 2008;4:85-7.
58. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005;25:2002-9. (Pubitemid 40289405)
59. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher III RJ, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 2010;107:9879-84.
60. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010;75:2017-20.
61. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011;8:267-80.
62. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007;170:658-66. (Pubitemid 47339402)
63. Hoglinger GU, Michel PP, Champy P, Feger J, Hirsch EC, Ruberg M, et al. Experimental evidence for a toxic etiology of tropical parkinsonism. Mov Disord 2005;20:118-9. (Pubitemid 40277523)
64. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002;277:1641-4. (Pubitemid 34968732)
65. Flynn MR, Susi P. Neurological risks associated with manganese exposure from welding operations - a literature review. Int JHyg EnvironHealth 2009;212:459-69.
66. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 2002;326:155-8. (Pubitemid 34722448)
67. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-6. (Pubitemid 34809355)
68. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-62. (Pubitemid 38857373)
69. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002;99:14524-9. (Pubitemid 35257704)
70. Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Ann NY Acad Sci 2004;1012:209-23. (Pubitemid 38453527)
71. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009;41:308-15.
72. Hong DP, Fink AL, Uversky VN. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta 2009;1794:282-90.
73. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein, implication for dopaminergic neurodegeneration. FEBS J 2005;272:3661-72. (Pubitemid 41021178)
74. Valente EM, Brancati F, Caputo V, Graham EA, Davis MB, Ferraris A, et al. PARK6 is a common cause of familial parkinsonism. Neurol Sci 2002;23(Suppl 2):S117-8.
75. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004;56:336-41. (Pubitemid 39166552)
76. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem2004;279:18614-22.
77. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 2004;101:9103-8. (Pubitemid 38781618)
78. Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res 2009;87:123-9.
79. Gandhi S, Muqit MM, Stanyer L, Healy DG, Abou-Sleiman PM, Hargreaves I, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006;129:1720-31. (Pubitemid 43999406)
80. Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007;27:12413-8. (Pubitemid 350085485)
81. Atsumi M, Li Y, Tomiyama H, Sato K, Hattori N. A 62-year-old woman with early-onset Parkinson's disease associated with the PINKi gene deletion. Rinsho Shinkeigaku 2006;46:199-202. (Pubitemid 43761969)
82. Henn IH, Bouman L, Schlehe JS, Schlierf A, Schramm JE, Wegener E, et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 2007;27:1868-78.
83. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000;97:13354-9.
84. Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004;13:R127-33 Spec No 1:.
85. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 2008;105:1638-43. (Pubitemid 351346567)
86. Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem 2003;278:47199-208. (Pubitemid 37452306)
87. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008;27:433-46. (Pubitemid 351161653)
88. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008;183:795-803.
89. Cookson MR. Pathways to Parkinsonism. Neuron 2003;37:7-10. (Pubitemid 36106428)
90. Bonifati V, Rizzu P, van BarenMJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-9. (Pubitemid 36131051)
91. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, et al. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 2003;24:159-60. (Pubitemid 37304291)
92. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004;5:213-8. (Pubitemid 38401204)
93. Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 2004;24:321-9. (Pubitemid 39336638)
94. Krebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 2010;5:e9367.
95. Burbulla LF, Krebiehl G, Kruger R. Balance is the challenge - the impact of mitochondrial dynamics in Parkinson's disease. Eur J Clin Invest 2010;40:1048-60.
96. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, et al. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 2010;29:3571-89.
97. Marongiu R, Ferraris A, Ialongo T, Michiorri S, Soleti F, Ferrari F, et al. PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat 2008;29:565.
98. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-62. (Pubitemid 46921058)
99. Hedrich K, KannM, Lanthaler AJ, Dalski A, Eskelson C, Landt O, et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 2001;10:1649-56. (Pubitemid 32776294)
100. Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002;52:849-53. (Pubitemid 35403199)
101. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6.
102. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003;179:9-16.
103. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003;23:10756-64. (Pubitemid 37499681)
104. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 2006;60:197-203.
105. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008;29:322-9.
106. Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol 2004;55:430-4. (Pubitemid 38269597)
107. Zhao B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem Res 2009;34:630-8.
108. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 2007;22:2242-8.
109. Nakaso K, Ito S, Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci Lett 2008;432:146-50.
110. Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, et al. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol 2008;167:553-60. (Pubitemid 351323310)
111. Chan P, Qin Z, Zheng Z, Zhang L, Fang X, Sun F, et al. A randomized, double-blind, placebo controlled, delayed start study to assess safety, tolerability and efficacy of green tea polyphenols in Parkinson's disease. XVIII WFN World Congress on Parkinson's Disease and Related Disorders; 2009. abstract.
112. Weinreb O, Amit T, Mandel S, Youdim MB. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 2009;4:283-96.
113. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009;41:1303-7.
114. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009;12:1129-35.
115. Chartier-Harlin MC, Dachsel J, Hulihan M, Kachergus J, Lepretre Le, Rhun E, et al. EIF4G1 mutations in familial parkinsonism. XVIIIWFN World Congress on Parkinson's Disease and Related Disorders; 2009. abstract No. 1154.